Clozapine rechallenge or continuation despite neutropenia or agranulocytosis using colony-stimulating factor: A systematic review.

Objectives: Rechallenge/continuation of clozapine in association with colony-stimulating factors (CSFs) following neutropenia/agranulocytosis has been reported, but many questions remain unanswered about efficacy and safety. This systematic review aims to assess the efficacy and safety of rechallenging/continuing clozapine in patients following neutropenia/agranulocytosis using CSFs.

Methods: MEDLINE, Embase, PsycInfo, and Web of Science databases were searched from inception date to July 31, 2022.

Management of Rhabdomyolysis in a Patient Treated with Clozapine: A Case Report and Clinical Recommendations.

Clozapine has a unique efficacy in treatment-resistant schizophrenia. Its use is, however, associated with potential adverse events. Among those, clozapine induced rhabdomyolysis can compromise clozapine treatment.

Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series.

Background: Clozapine has a unique efficacy profile among individuals suffering from treatment-resistant schizophrenia, but is associated with hematological side effects. The use of granulocyte colony-stimulating factors (G-CSF) to allow clozapine continuation or rechallenge has emerged as a promising option, but evidence is still scarce.

Aim: To describe the largest case series so far published regarding this practice.